Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sacituzumab tirumotecan plus pembrolizumab with or without bevacizumab versus standard maintenance therapy in first-line persistent, recurrent, or metastatic PD-L1-positive cervical cancer
MOH_2025-11-17_015470Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan, pembrolizumab and bevacizumab in Cervical Cancer (CC) (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on MOH_2025-11-17_015470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-17_015470.